{
    "clinical_study": {
        "@rank": "110821", 
        "acronym": "DDM2", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One placebo pill daily for 1 year"
            }, 
            {
                "arm_group_label": "cholecalciferol", 
                "arm_group_type": "Active Comparator", 
                "description": "One cholecalciferol pill daily for 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "This research study in adults with established type 2 diabetes will test whether daily\n      vitamin D supplementation affects how the body processes glucose (sugar)."
        }, 
        "brief_title": "Vitamin D for Established Type 2 Diabetes (DDM2)", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Established type 2 diabetes, defined by one of the following two criteria:\n\n          -  Age \u2265 25 years and \u2264 75 years\n\n          -  BMI: 23 to 40 kg/m2 inclusive\n\n          -  Provision of signed and dated written informed consent prior to any study procedures.\n\n        Major Exclusion Criteria\n\n          -  \"Severe\" diabetes defined by one of the following criteria:\n\n          -  - (a) Symptoms of hyperglycemia;\n\n          -  - (b) Screening HbA1c \u2265 7.5 [may indicate potential for rapid progression during the\n             trial necessitating need to amplify diabetes-specific pharmacotherapy]\n\n          -  History of nephrolithiasis or hypercalcemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736865", 
            "org_study_id": "DK76092-06", 
            "secondary_id": "R01DK076092"
        }, 
        "intervention": [
            {
                "arm_group_label": "cholecalciferol", 
                "intervention_name": "Cholecalciferol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cholecalciferol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 24, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ddm2@tuftsmedicalcenter.org", 
                    "last_name": "Paul Fuss", 
                    "phone": "617-636-2834"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }, 
                "investigator": {
                    "last_name": "Anastassios Pittas, MD MS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "MaryColleen.Rogge@va.gov", 
                    "last_name": "Colleen Rogge", 
                    "phone": "513-475-6478"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Cincinnati VA Medical Center"
                }, 
                "investigator": {
                    "last_name": "David D'Alessio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "other_outcome": [
            {
                "measure": "Hemoglobin A1c", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Change in diabetes medications", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "description": "Variability of response to vitamin D supplementation in subgroups defined by baseline characteristics: (1) race; (3) 25OHD concentration; (3) diabetes treatment.", 
                "measure": "Variability of response to vitamin D supplementation in subgroups.", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Effect of vitamin D supplementation on blood 25-hydroxyvitaminD concentration", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "description": "Cardiovascular risk factors defined as blood pressure, lipid profile, C-reactive protein and urine albumin excretion", 
                "measure": "Cardiovascular risk factors", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disposition index by the insulin secretion sensitivity index-2 (ISSI-2)", 
            "measure": "Disposition index", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736865"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change in glycemia (categorical variable, composite outcome) defined as [1] a decrease in diabetes medications or [2] a reduction of equal to or more than 0.4 HbA1c units from baseline without increasing medications.", 
            "measure": "Change in glycemia", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "source": "Tufts Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Tufts Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}